Elanco Launches Befrena for Canine Allergy and Itch Relief
Indianapolis, Indiana, USA – May 18, 2026 Elanco Animal Health Incorporated announced the phased U.S. launch of Befrena™ (tirnovetmab),...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Indianapolis, Indiana, USA – May 18, 2026 Elanco Animal Health Incorporated announced the phased U.S. launch of Befrena™ (tirnovetmab),...
PARSIPPANY, N.J., December 5, 2025 — Zoetis Inc. announced that Health Canada has approved Portela™ (relfovetmab injection) for the...
SAN FRANCISCO, December 3, 2025 — Junevity today announced the expansion of its seed funding round to $20 million...
PARSIPPANY, N.J., December 3, 2025 — Zoetis has highlighted its R&D leadership, expanding innovation strategy, and long-term growth outlook...
San Diego, CA – September 23, 2025 — Gallant, an animal-health biotechnology company specializing in regenerative medicine, announced that...
